The important thing is that these trials can only be performed on the young and healthy who are at the least risk of severe illness and death. This means any re

The important thing is that these trials can only be performed on the young and healthy who are at the least risk of severe illness and death. This means any results gained from these would have been essentially worthless when it comes to the patients most at risk. Consequently, one would have still had to run the regular P3 trials with a diverse group of subjects. Therefore, any acceleration in the vaccine's development process would have at best been marginal. This is also what the industry association of German drug manufacturers has pointed out in a statement, dismissing the British challenge trials as ethically dubious and effectively useless.